Medication info
Olmetin Tablet 20/5 mg

Olmetin Tablet 20/5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
White or yellowish round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]
Approval status
Active

MFDS item code 202003952 · Approved 2020.05.28 · Insurance code 671706540

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is required when this medicine is administered to elderly patients aged 65 years or older. No overall differences in efficacy or safety have been observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, and the dose may be increased to a maximum of 20 mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, the treatment goal, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Children under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease.
View approved original text

This medication is used for patients who need to take Olmesartan Medoxomil and Rosuvastatin together. Olmesartan Medoxomil is effective for the treatment of essential hypertension. Rosuvastatin, on the other hand, is used as an adjunct in patients with hypercholesterolemia and hyperlipidemia when dietary adjustments and exercise alone do not suffice. Additionally, it helps reduce cholesterol levels in patients with homozygous familial hypercholesterolemia and delays the progression of atherosclerosis when used in conjunction with other therapies. It is also effective in reducing the risks of stroke, myocardial infarction, and artery revascularization in patients at high risk for cardiovascular diseases. Therefore, this medication is used to treat both hypertension and dyslipidemia concurrently.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is required when this medicine is administered to elderly patients aged 65 years or older. No overall differences in efficacy or safety have been observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, and the dose may be increased to a maximum of 20 mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, the treatment goal, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Children under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, if pregnancy is confirmed, it should be discontinued immediately. Those allergic to this medication or its components, pregnant or potentially pregnant women, breastfeeding women, and individuals with certain kidney or liver diseases should not take this medication. Patients with kidney dialysis, severe renal failure, severe liver impairment, biliary obstruction, or muscle disease should avoid taking this medication or proceed with caution. This medication contains lactose, so those with lactose intolerance or certain genetic metabolic disorders should not take it. Patients with low blood pressure or reduced blood volume may experience symptoms of hypotension upon initial use of this medicine, thus requiring careful monitoring by health care personnel. Patients with impaired kidney function or kidney transplant recipients should have serum potassium and creatinine levels regularly checked, and those with renal artery stenosis should be cautious as well. This medication can raise blood potassium levels, and patients at risk for hyperkalemia should regularly monitor their serum potassium concentration. Patients with aortic or mitral valve stenosis, as well as obstructive or hypertrophic heart disease, require special caution when taking this medication. This medication may cause dizziness, so caution is advised when driving or operating hazardous machinery. Individuals with a history of liver disease or excessive alcohol consumption should undergo regular liver function tests before and during treatment with this medication. Muscle pain or myopathy, and rarely rhabdomyolysis may occur; therefore, if symptoms of muscle pain or weakness develop, health care personnel should be notified immediately. Taking this medication alongside certain drugs (e.g., potassium-sparing diuretics, non-steroidal anti-inflammatory drugs, lithium, etc.) may increase the risk of side effects due to interactions, so caution is warranted. Pregnant or possibly pregnant women must use appropriate contraceptive methods and discontinue the medication immediately if there is a pregnancy. Breastfeeding women may have adverse effects on their infants when using this medication, so either breastfeeding should be terminated or the medication should be discontinued. This medication is not recommended for use in children under the age of 18, as safety and efficacy have not been established. Elderly patients may have increased serum concentrations of this medication, thus requiring dosage adjustment and caution. In the case of overdose, symptoms like hypotension and palpitations may occur, and symptomatic treatment should be provided as necessary. This medication should be kept out of the reach of children and should not be transferred to other containers.

Side effects

Increased ALT, increased AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromyopathy, drowsiness, gastroesophageal reflux, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal rigidity, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial swelling, asthenia, vascular edema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), palpitations, increased blood pressure, low back pain, increased blood creatinine, diarrhea, chest pain, cough, nasal bleeding, upper respiratory infection, asthma, hypersensitivity reaction including vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. Moreover, it is important to store it at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.